EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 172 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR Jennifer Garner Shared A Video Of Her Mammogram Appointment October 21, 2019 Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... September 1, 2022 Immunotherapy Effective in Alveolar Soft Part Sarcoma January 9, 2019 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS Longer Duration of Treatment with ICIs Associated with a Higher Rate... T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... Thank you!
